Here’s what you should know:
1. Dr. Boubekeur will oversee the company’s research and development, as well as business development and licensing.
2. At AstraZeneca, she was vice president of emerging portfolio and search and evaluation. She has more than 30 years of experience in pharmaceuticals, with previous roles at Novartis and Roche.
3. Dr. Boubekeur said, “I am delighted to join Tillotts and the Zeria Group and to be part of a growing team dedicated to improving the quality of life of patients suffering from GI-related diseases. I look forward to working alongside [research and development] leaders, talented employees and partners to build on our core business, drive profitable growth and embrace operational excellence.”
4. Tillotts develops products exclusively for the digestive system, currently focusing on inflammatory bowel disease.
More articles on gastroenterology:
Medical Facilities Corp.’s new $150M credit line could fuel acquisitions — 3 insights
Olean General Hospital refuses to ‘pay millions of dollars more than necessary’ for local anesthesia provider — 5 insights
‘The best screening test is the one that gets done:’ 5 Qs with professional golfer Tom Lehman, CRC survivor
